Impact of the zero-markup drug policy on hospitalisation expenditure in western rural China: an interrupted time series analysis

Tropical Medicine and International Health

Volumn 22, Issue 2, 2017, Pages 180-186

  Yang, Caijun ^a   Shen, Qian ^a   Cai, Wenfang ^a   Zhu, Wenwen ^a   Li, Zongjie ^a   Wu, Lina ^a   Fang, Yu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

China; hospitalisation expenditure; interrupted time series analysis; National Essential Medicines Policy; zero markup drug policy

Indexed keywords

DRUG; FINANCIAL SYSTEM; HEALTH EXPENDITURE; HEALTH INSURANCE; HEALTH POLICY; HOSPITAL SECTOR; MEDICAL GEOGRAPHY; MEDICINE; NUMERICAL MODEL; REGRESSION ANALYSIS; RURAL AREA; TIME SERIES ANALYSIS;

ARTICLE; CHINA; HEALTH CARE POLICY; HEALTH SERVICE; HOSPITAL RUNNING COST; QUANTITATIVE STUDY; REGRESSION ANALYSIS; REIMBURSEMENT; RURAL POPULATION; TIME SERIES ANALYSIS; ZERO MARKUP DRUG POLICY; DRUG COST; ECONOMICS; HOSPITALIZATION; HUMAN; RURAL HEALTH CARE; TRENDS;

CHINA; FENG; SHAANXI;

ESSENTIAL DRUG;

CHINA; DRUG COSTS; DRUGS, ESSENTIAL; HOSPITALIZATION; HUMANS; RURAL HEALTH SERVICES;

EID: 85007228141     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12817     Document Type: Article

References (23)

1. Chinese Ministry of Health. Financial Report of Medical Institutions. Chinese Ministry of Health: Beijing, China, 2010.
2. Zhang X, Wu Q, Liu G et al. The effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centers: evidence from a longitudinal study. BMJ Open 2014: 4: e006471–e006471.
3. Yip W, Mahal A. The health care systems of China and India: performance and future challenges. Health Affair 2008: 27: 921–932.
4. National Health Development Research Center (NHDRC). China National Health Accounts Report. National Health Development Research Center (NHDRC): Beijing, China, 2013.
5. Yi H, Mller G, Zhang L, Li S, Rozelle S. Intended and unintended consequences of China's zero markup drug policy. Health Affair 2015: 34: 1391–1398.
6. Liu S, Xu H, Cui X, Qian Y. How the implementation of drug zero markup policy will affect health care expenditure in hospitals: observation and prediction based on Zhejiang model. Value Health 2014: 17: A790.
7. Wang H, Tang Y, Liu Y, Yang L, Zhang X. Effect evaluation of national essential medicine system in China: based on survey data from Shandong, Hubei and Sichuan. Chin J Health Policy 2012: 5: 30–34.
8. Sun Q, Zuo G, Li K, Meng Q, He P. Whether the essential medicine policy decreases the medical cost of rural population: experience from three counties in Anhui Province. Chin Health Econ 2012: 31: 65–67.
9. Yang L, Liu C, Ferrier JA, Zhou W, Zhang X. The impact of the National Essential Medicines Policy on prescribing behaviours in primary care facilities in Hubei Province of China. Health Policy Plann 2013: 28: 750–760.
10. Song Y, Bian Y. Impact evaluation of essential medicine system on prescription charges in township hospitals of Shandong Province. Chin Health Service Manage 2012: 8: 586–587.
11. Shi Y, Li W. Effect evaluation and consideration of essential drug system in Beijing Xicheng District around 6 years before and after the implementation of the System. China Pharm 2013: 24: 300–302.
12. Zhou Z, Su Y, Campbell B et al. The financial impact of the ‘zero-markup policy for essential drugs’ on patients in county hospitals in western rural China. PLoS ONE 2015: 10: e0121630.
13. Wikipedia. Shaanxi. 1 April 2016. (Available from: http://en.wikipedia.org/wiki/Shaanxi) [20 May 2016].
14. WHO. The western area health initiative, 2012. (Available from: http://www.wpro.who.int/china/areas/western_area_health_initiative/en/) [20 May 2016].
15. Shaanxi Health Department. Notice on implementing the national essential drug system, 25 December 2009. (Available from: http://www.sxwjw.gov.cn/newstyle/pub_newsshow.asp?id=1017195&chid=100207) [20 May 2016].
16. Cook TD, Campbell DT. Quasi-Experimentation: Design & Analysis Issues for Field Settings. Houghton Mifflin Company: Boston, MA, 1979.
17. Rashidian A, Joudaki H, Khodayari-Moez E, Omranikhoo H, Geraili B, Arab M. The impact of rural health system reform on hospitalization rates in the Islamic Republic of Iran: an interrupted time series. Bull World Health Organ 2013: 91: 942–949.
18. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002: 27: 299–309.
19. Anonymous. Module 5, time series analysis. In: Anonymous, ed. Pharmacoepidemiology: Behavioral and Cultural Themes. Center for Clinical Epidemiology and Biostatistics Australia: Newcastle, 2001.
20. Ramsey CR. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. Int J Technol Assess 2003: 19: 613–623.
21. Kutner MH, Nachtsheim CJ, Neter J. Applied Linear Regression Models (4th edn), Irwin/McGraw-Hill: Chicago, 2004.
22. Hamilton I, LIoyd C, Hewitt C, Godfrey C. Effect of reclassification of cannabis on hospital admissions for cannabis psychosis: a time series analysis. Int J Drug Policy 2014: 25: 151–156.
23. Gillings D, Makuc D, Siegel E. Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. Am J Public Health 1981: 71: 38–46.